Latest Episode
Peter Sandercock and IST-3
Acute ischemic stroke is a major public health burden and globally a common cause of death and disability
Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.
Ways To Listen To This Podcast
1) Use your own podcast software
Add the URL below to your podcast software:
https://wiley-blackwell.jellycast.com/podcast/feed/25
3) Use our Podcast Player (requires Flash)
Select an episode from the drop down menu below and the podcast will autoplay. Press the circular button to stop.
You need to download the flash player from Adobe.
Note: if no player is visible you will need to install the
Flash Player plugin.
